HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 3 (March)

1. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
   Arch Intern Med, 165(4): 416-23. [Abstract] [Full-text]
2. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan.
   Arch Intern Med, 165(4): 409-15. [Abstract] [Full-text]
3. Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.
   Infect Genet Evol, 5(3): 247-53. [Abstract] [Full-text]
4. Evidence for negative selective pressure in HIV-2 evolution in vivo.
   Infect Genet Evol, 5(3): 239-46. [Abstract] [Full-text]
5. HIV-1 genetic variants circulation in the North of Angola.
   Infect Genet Evol, 5(3): 231-7. [Abstract] [Full-text]
6. Re-analysis of 34 full-length HIV-1 intersubtype recombinant sequences.
   Infect Genet Evol, 5(3): 225-9. [Abstract] [Full-text]
7. Analysis of complex HIV-1 intersubtype recombinants using a Bayesian scanning method.
   Infect Genet Evol, 5(3): 219-24. [Abstract] [Full-text]
8. The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF.
   Infect Genet Evol, 5(3): 209-17. [Abstract] [Full-text]
9. Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth.
   Infect Genet Evol, 5(3): 199-208. [Abstract] [Full-text]
10. HIV-1 Tat modulates T-bet expression and induces Th1 type of immune response.
    Biochem Biophys Res Commun, 329(2): 706-12. [Abstract] [Full-text]
11. Influence of membrane fluidity on human immunodeficiency virus type 1 entry.
    Biochem Biophys Res Commun, 329(2): 480-6. [Abstract] [Full-text]
12. Discordant resistance interpretations in multi-treated HIV-1 patients.
    Int J Antimicrob Agents, 25(3): 211-5. [Abstract] [Full-text]
13. One-step nested PCR for detection of 2 LTR circles in PBMCs of HIV-1 infected patients with no detectable plasma HIV RNA.
    J Virol Methods, 125(1): 11-3. [Abstract] [Full-text]
14. Integrase inhibitors to treat HIV/AIDS.
    Nat Rev Drug Discov, 4(3): 236-48. [Abstract] [Full-text]
15. The cysteine residues of HIV-1 capsid regulate oligomerization and cyclophilin A-induced changes.
    Biophys J, 88(3): 2078-88. [Abstract] [Full-text]
16. The effect of cellular receptor diffusion on receptor-mediated viral binding using Brownian adhesive dynamics (BRAD) simulations.
    Biophys J, 88(3): 1666-75. [Abstract] [Full-text]
17. Virus-like particles as HIV-1 vaccines.
    Rev Med Virol, 15(2): 75-88. [Abstract] [Full-text]
18. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
    Nucleic Acids Res, 33(4): 1249-56. [Abstract] [Full-text]
19. Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus.
    Biomed Pharmacother, 59(1): 47-50. [Abstract] [Full-text]
20. Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers.
    Biomed Pharmacother, 59(1): 38-46. [Abstract] [Full-text]
21. A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.
    Virus Genes, 30(1): 127-31. [Abstract] [Full-text]
22. Functional variability of Rev response element in HIV-1 primary isolates.
    Virus Genes, 30(1): 23-9. [Abstract] [Full-text]
23. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    J Infect Dis, 191(7): 1164-8. [Abstract] [Full-text]
24. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    J Infect Dis, 191(7): 1155-63. [Abstract] [Full-text]
25. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions.
    Am J Obstet Gynecol, 192(3): 774-9. [Abstract] [Full-text]
26. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics.
    Trends Immunol, 26(3): 166-71. [Abstract] [Full-text]
27. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.
    Am J Med, 118(3): 292-300. [Abstract] [Full-text]
28. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
    Science, 307(5714): 1434-40. [Abstract] [Full-text]
29. Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature.
    J Clin Microbiol, 43(3): 1465-6. [Abstract] [Full-text]
30. Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.
    J Clin Microbiol, 43(3): 1439-42. [Abstract] [Full-text]
31. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.
    J Clin Microbiol, 43(3): 1395-400. [Abstract] [Full-text]
32. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Virology, 334(1): 124-33. [Abstract] [Full-text]
33. Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways.
    Virology, 334(1): 59-73. [Abstract] [Full-text]
34. Tumor necrosis factor-alpha stimulates HIV-1 production in primary culture of human adipocytes.
    Exp Cell Res, 304(2): 544-51. [Abstract] [Full-text]
35. Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses.
    Immunol Cell Biol, 83(2): 129-43. [Abstract] [Full-text]
36. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
    J Biol Chem, 280(10): 9345-53. [Abstract] [Full-text]
37. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles.
    Biochem Biophys Res Commun, 329(3): 917-24. [Abstract] [Full-text]
38. HIV and human complement: inefficient virolysis and effective adherence.
    Immunol Lett, 97(2): 209-14. [Abstract] [Full-text]
39. Tongue disease in advanced AIDS.
    Oral Dis, 11(2): 72-80. [Abstract] [Full-text]
40. A complementary single-stranded docking site is required for enhancement of strand exchange by human immunodeficiency virus nucleocapsid protein on substrates that model viral recombination.
    Biochemistry, 44(10): 3915-25. [Abstract] [Full-text]
41. Illustration of HIV-1 protease folding through a molten-globule-like intermediate using an experimental model that implicates alpha-crystallin and calcium ions.
    Biochemistry, 44(10): 3725-34. [Abstract] [Full-text]
42. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Vaccine, 23(17): 2164-7. [Abstract] [Full-text]
43. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients--an extended open trial.
    Vaccine, 23(17): 2149-53. [Abstract] [Full-text]
44. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".
    Vaccine, 23(17): 2066-73. [Abstract] [Full-text]
45. Experimental components analysis of brief theory-based HIV/AIDS risk-reduction counseling for sexually transmitted infection patients.
    Health Psychol, 24(2): 198-208. [Abstract] [Full-text]
46. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness.
    Proc Natl Acad Sci U S A, 102(10): 3760-5. [Abstract] [Full-text]
47. Gene therapy progress and prospects: novel gene therapy approaches for AIDS.
    Gene Ther, 12(6): 467-76. [Abstract] [Full-text]
48. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.
    Mem Inst Oswaldo Cruz, 99(8): 877-82. [Abstract] [Full-text]
49. The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida.
    Mem Inst Oswaldo Cruz, 99(8): 789-93. [Abstract] [Full-text]
50. Adenovirus vector-based vaccines for human immunodeficiency virus type 1.
    Hum Gene Ther, 16(2): 149-56. [Abstract] [Full-text]
51. Rural perspectives on HIV/AIDS prevention: a comparative study of Thailand and Ghana.
    Health Policy, 72(1): 25-40. [Abstract] [Full-text]
52. Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during AIDS-associated cryptococcosis.
    Clin Microbiol Infect, 11(4): 296-300. [Abstract] [Full-text]
53. Latex bead immobilisation in PDMS matrix for the detection of p53 gene point mutation and anti-HIV-1 capsid protein antibodies.
    Anal Bioanal Chem, 381(5): 1019-24. [Abstract] [Full-text]
54. Lichtenstein repair of inguinal hernia with Surgisis inguinal hernia matrix soft-tissue graft in immunodepressed patients.
    Hernia, 9(1): 29-31. [Abstract] [Full-text]
55. A peer-based substance abuse intervention for HIV+ rural women: a pilot study.
    Arch Psychiatr Nurs, 19(1): 10-7. [Abstract] [Full-text]
56. Donkey work: women, religion, and HIV/AIDS in Malawi.
    Health Care Women Int, 26(1): 4-16. [Abstract] [Full-text]
57. The impact of improved self-efficacy on HIV viral load and distress in culturally diverse women living with AIDS: the SMART/EST Women's Project.
    AIDS Care, 17(2): 222-36. [Abstract] [Full-text]
58. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.
    Clin Exp Immunol, 140(1): 138-48. [Abstract] [Full-text]
59. The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells.
    J Biol Chem, 280(11): 10548-55. [Abstract] [Full-text]
60. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.
    Glia, 50(2): 91-106. [Abstract] [Full-text]
61. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation.
    J Virol, 79(7): 4479-91. [Abstract] [Full-text]
62. TFII-I regulates induction of chromosomally integrated human immunodeficiency virus type 1 long terminal repeat in cooperation with USF.
    J Virol, 79(7): 4396-406. [Abstract] [Full-text]
63. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
    J Virol, 79(7): 4357-68. [Abstract] [Full-text]
64. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    J Virol, 79(7): 4347-56. [Abstract] [Full-text]
65. Tetraspanin CD81 provides a costimulatory signal resulting in increased human immunodeficiency virus type 1 gene expression in primary CD4+ T lymphocytes through NF-kappaB, NFAT, and AP-1 transduction pathways.
    J Virol, 79(7): 4316-28. [Abstract] [Full-text]
66. Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection.
    J Virol, 79(7): 4289-97. [Abstract] [Full-text]
67. Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.
    J Virol, 79(7): 4257-69. [Abstract] [Full-text]
68. Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor.
    J Virol, 79(7): 4140-9. [Abstract] [Full-text]
69. Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.
    J Virol, 79(7): 4132-9. [Abstract] [Full-text]
70. Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells by biarsenical labeling.
    J Virol, 79(7): 4055-65. [Abstract] [Full-text]
71. Analysis of human immunodeficiency virus cytopathicity by using a new method for quantitating viral dynamics in cell culture.
    J Virol, 79(7): 4025-32. [Abstract] [Full-text]
72. Suicide risk and mental health indicators: Do they differ by abuse and HIV status?
    Womens Health Issues, 15(2): 89-95. [Abstract] [Full-text]
73. HIV and male circumcision--a systematic review with assessment of the quality of studies.
    Lancet Infect Dis, 5(3): 165-73. [Abstract] [Full-text]
74. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly.
    Cell, 120(5): 663-74. [Abstract] [Full-text]
75. Induction of secretory aspartyl proteinase of Candida albicans by HIV-1 but not HSV-2 or some other microorganisms associated with vaginal environment.
    Mycopathologia, 159(2): 213-8. [Abstract] [Full-text]
76. Electrophoretic karyotypes of C. neoformans serotype A recovered from Thai patients with AIDS.
    Mycopathologia, 159(2): 189-97. [Abstract] [Full-text]
77. The cellular HIV-1 Rev cofactor hRIP is required for viral replication.
    Proc Natl Acad Sci U S A, 102(11): 4027-32. [Abstract] [Full-text]
78. A comparison of HIV seropositive and seronegative young adult heroin- and cocaine-using men who have sex with men in New York City, 2000-2003.
    J Urban Health, 82(1): i51-61. [Abstract] [Full-text]
79. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men.
    J Urban Health, 82(1): i62-70. [Abstract] [Full-text]
80. Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use.
    J Urban Health, 82(1): i120-6. [Abstract] [Full-text]
81. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
    Ann Pharmacother, 39(4): 603-9. [Abstract] [Full-text]
82. Measuring HIV vaccine efficacy.
    Stat Med, 24(7): 983-92. [Abstract] [Full-text]
83. Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.
    Mol Ther, 11(4): 645-51. [Abstract] [Full-text]
84. Increases in a marker of immune system reconstitution are predated by decreases in 24-h urinary cortisol output and depressed mood during a 10-week stress management intervention in symptomatic HIV-infected men.
    J Psychosom Res, 58(1): 3-13. [Abstract] [Full-text]
85. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial.
    Aliment Pharmacol Ther, 21(6): 757-63. [Abstract] [Full-text]
86. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
    J Med Chem, 48(6): 2072-9. [Abstract] [Full-text]
87. Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
    J Med Chem, 48(6): 1965-73. [Abstract] [Full-text]
88. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
    J Med Chem, 48(6): 1948-64. [Abstract] [Full-text]
89. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
    J Med Chem, 48(6): 1813-22. [Abstract] [Full-text]
90. ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis.
    Cell Death Differ, 12(4): 326-34. [Abstract] [Full-text]
91. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.
    J Infect Dis, 191(8): 1325-30. [Abstract] [Full-text]
92. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.
    J Infect Dis, 191(8): 1321-4. [Abstract] [Full-text]
93. The challenges of HIV vaccine development and testing.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 277-91. [Abstract] [Full-text]
94. HIV and cancer of the cervix.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 269-76. [Abstract] [Full-text]
95. Laboratory markers associated with progression of HIV infection.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 243-54. [Abstract] [Full-text]
96. HIV and gynaecological infections.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 231-41. [Abstract] [Full-text]
97. Adaptive evolution in perinatal HIV-1.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 211-29. [Abstract] [Full-text]
98. Breastfeeding and HIV.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 185-96. [Abstract] [Full-text]
99. Management of human immunodeficiency virus infection in pregnancy.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 169-83. [Abstract] [Full-text]
100. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
     J Immunol Methods, 297(1): 187-201. [Abstract] [Full-text]
101. Regulation of HIV-1 env mRNA translation by Rev protein.
     Biochim Biophys Acta, 1743(1): 169-75. [Abstract] [Full-text]
102. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity.
     J Clin Invest, 115(3): 765-73. [Abstract] [Full-text]
103. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
     J Biol Chem, 280(12): 11259-73. [Abstract] [Full-text]
104. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.
     J Exp Med, 201(6): 891-902. [Abstract] [Full-text]
105. The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions.
     Antiviral Res, 66(1): 67-78. [Abstract] [Full-text]
106. Involvement of HIV-1 protease in virus-induced cell killing.
     Antiviral Res, 66(1): 47-55. [Abstract] [Full-text]
107. Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication.
     Antiviral Res, 66(1): 13-22. [Abstract] [Full-text]
108. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.
     Lancet, 365(9464): 1031-8. [Abstract] [Full-text]
109. The virion-associated Gag-Pol is decreased in chimeric Moloney murine leukemia viruses in which the readthrough region is replaced by the frameshift region of the human immunodeficiency virus type 1.
     Virology, 334(2): 342-52. [Abstract] [Full-text]
110. Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART.
     Virology, 334(2): 299-305. [Abstract] [Full-text]
111. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels.
     Virology, 334(2): 294-8. [Abstract] [Full-text]
112. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro.
     Virology, 334(2): 264-75. [Abstract] [Full-text]
113. Potent inhibition of HIV-1 entry by (s4dU)35.
     Virology, 334(2): 214-23. [Abstract] [Full-text]
114. Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation.
     Virology, 334(2): 178-93. [Abstract] [Full-text]
115. Apoptosis as a mechanism of natural resistance to HIV-1 infection in an exposed but uninfected population.
     J Clin Virol, 32(4): 329-35. [Abstract] [Full-text]
116. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
     J Clin Virol, 32(4): 294-9. [Abstract] [Full-text]
117. RNA extraction prior to HIV-1 resistance detection using Line Probe Assay (LiPA): comparison of three methods.
     J Clin Virol, 32(4): 265-71. [Abstract] [Full-text]
118. Temperament and risky behaviors: a pathway to HIV?
     J Affect Disord, 85(1): 191-200. [Abstract] [Full-text]
119. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases.
     Kidney Int, 67(4): 1381-90. [Abstract] [Full-text]
120. Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity.
     Biochemistry, 44(12): 4648-55. [Abstract] [Full-text]
121. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein.
     Blood, 105(7): 2802-11. [Abstract] [Full-text]
122. Seroprevalence of human herpesvirus 8 infection in children born to HIV-1-infected women in São Paulo, Brazil.
     Braz J Med Biol Res, 38(2): 237-40. [Abstract] [Full-text]
123. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
     J Gen Virol, 86: 1171-9. [Abstract] [Full-text]
124. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.
     JAMA, 293(12): 1471-6. [Abstract] [Full-text]
125. The urological management of the patient with acquired immunodeficiency syndrome.
     BJU Int, 95(5): 709-16. [Abstract] [Full-text]
126. Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups.
     Proc Natl Acad Sci U S A, 102(12): 4425-9. [Abstract] [Full-text]
127. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
     Proc Natl Acad Sci U S A, 102(12): 4512-7. [Abstract] [Full-text]
128. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
     Gene Ther, 12(7): 597-606. [Abstract] [Full-text]
129. Semen characteristics in human immunodeficiency virus (HIV)- and hepatitis C (HCV)-seropositive males: predictors of the success of viral removal after sperm washing.
     Hum Reprod, 20(4): 1028-34. [Abstract] [Full-text]
130. Significance of the detection of HIV-1 gag- and/or pol-CD8/A2 T-lymphocytes in HIV-patients.
     Immunol Lett, 98(1): 73-81. [Abstract] [Full-text]
131. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
     Int Immunol, 17(4): 469-75. [Abstract] [Full-text]
132. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.
     J Antimicrob Chemother, 55(4): 410-2. [Abstract] [Full-text]
133. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
     J Antimicrob Chemother, 55(4): 413-6. [Abstract] [Full-text]
134. Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
     Antimicrob Agents Chemother, 49(4): 1576-9. [Abstract] [Full-text]
135. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1.
     J Med Virol, 76(1): 24-32. [Abstract] [Full-text]
136. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
     J Med Virol, 76(1): 1-6. [Abstract] [Full-text]
137. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
     J Med Virol, 76(1): 7-15. [Abstract] [Full-text]
138. Determination of HIV-1 subtypes (A-D, F, G, CRF01_AE) by PCR in the transmembrane region (gp41) with novel primers.
     J Med Virol, 76(1): 16-23. [Abstract] [Full-text]
139. Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases.
     J Biol Chem, 280(13): 12190-200. [Abstract] [Full-text]
140. HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor.
     J Leukoc Biol, 77(4): 522-34. [Abstract] [Full-text]
141. Short communication: pitfalls of culturing C8166 cells in serum-free media.
     AIDS Res Hum Retroviruses, 21(3): 246-8. [Abstract] [Full-text]
142. Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians.
     AIDS Res Hum Retroviruses, 21(3): 239-45. [Abstract] [Full-text]
143. Short communication: HIV type 1 phenotype, tropism, and sequence patterns: association and preference.
     AIDS Res Hum Retroviruses, 21(3): 234-8. [Abstract] [Full-text]
144. IL-8 increases transmission of HIV type 1 in cervical explant tissue.
     AIDS Res Hum Retroviruses, 21(3): 228-33. [Abstract] [Full-text]
145. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy.
     AIDS Res Hum Retroviruses, 21(3): 221-7. [Abstract] [Full-text]
146. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.
     AIDS Res Hum Retroviruses, 21(3): 207-13. [Abstract] [Full-text]
147. Travel patterns and risk behaviour of HIV-positive people travelling internationally.
     CMAJ, 172(7): 884-8. [Abstract] [Full-text]
148. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification.
     Arch Intern Med, 165(6): 690-5. [Abstract] [Full-text]
149. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users.
     Arch Intern Med, 165(6): 618-23. [Abstract] [Full-text]
150. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.
     J Virol, 79(8): 5232-7. [Abstract] [Full-text]
151. Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1.
     J Virol, 79(8): 5220-6. [Abstract] [Full-text]
152. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.
     J Virol, 79(8): 5203-10. [Abstract] [Full-text]
153. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
     J Virol, 79(8): 5185-202. [Abstract] [Full-text]
154. A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.
     J Virol, 79(8): 5142-52. [Abstract] [Full-text]
155. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
     J Virol, 79(8): 5000-5. [Abstract] [Full-text]
156. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
     J Virol, 79(8): 4991-9. [Abstract] [Full-text]
157. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.
     J Virol, 79(8): 4927-35. [Abstract] [Full-text]
158. Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline.
     J Virol, 79(8): 4908-17. [Abstract] [Full-text]
159. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.
     J Virol, 79(8): 4828-37. [Abstract] [Full-text]
160. Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion.
     J Virol, 79(8): 4720-9. [Abstract] [Full-text]
161. Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.
     J Virol, 79(8): 4580-8. [Abstract] [Full-text]
162. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.
     J Virol Methods, 125(2): 99-109. [Abstract] [Full-text]
163. Prevalence of human Papilloma Virus in HIV-positive and HIV-negative patients in the State of Bahia: a pilot study.
     Braz J Infect Dis, 8(5): 356-62. [Abstract] [Full-text]
164. Awareness, acceptance, and action: an emerging framework for understanding AIDS stigmatizing attitudes among community leaders in Barbados.
     AIDS Patient Care STDS, 19(3): 186-99. [Abstract] [Full-text]
165. Body image in patients with HIV/AIDS: assessment of a new psychometric measure and its medical correlates.
     AIDS Patient Care STDS, 19(3): 150-6. [Abstract] [Full-text]
166. Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era.
     AIDS Patient Care STDS, 19(3): 141-9. [Abstract] [Full-text]
167. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
     AIDS Patient Care STDS, 19(3): 135-40. [Abstract] [Full-text]
168. MHC polymorphism: AIDS susceptibility in non-human primates.
     Trends Immunol, 26(4): 227-33. [Abstract] [Full-text]
169. Identification of amino acids that promote specific and rigid TAR RNA-tat protein complex formation.
     Chem Biol, 12(3): 329-37. [Abstract] [Full-text]
170. Adolescent adjustment before and after HIV-related parental death.
     J Consult Clin Psychol, 73(2): 221-8. [Abstract] [Full-text]
171. The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy.
     Sex Transm Infect, 81(2): 120-3. [Abstract] [Full-text]
172. Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS.
     Int J Cancer, 115(2): 296-300. [Abstract] [Full-text]
173. The functionally conserved nucleoporins Nup124p from fission yeast and the human Nup153 mediate nuclear import and activity of the Tf1 retrotransposon and HIV-1 Vpr.
     Mol Biol Cell, 16(4): 1823-38. [Abstract] [Full-text]
174. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity.
     J Cell Physiol, 203(3): 547-56. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.